Weiss Ratings Reaffirms "Sell (D-)" Rating for Capricor Therapeutics (NASDAQ:CAPR)

Key Points

• Weiss Ratings has reiterated a "Sell (D-)" rating for Capricor Therapeutics (NASDAQ:CAPR) after a research report was issued on Wednesday.
• Despite the "Sell" rating from Weiss, other analysts have given favorable ratings, with a consensus of "Moderate Buy" and an average price target of $22.25 for the stock.
• Capricor Therapeutics has seen a recent decrease in stock value, trading down 0.3% to $7.48, with a market cap of $341.99 million.

Capricor Therapeutics (NASDAQ:CAPR - Get Free Report)'s stock had its "sell (d-)" rating reiterated by investment analysts at Weiss Ratings in a research report issued on Wednesday,Weiss Ratings reports.

A number of other equities analysts also recently weighed in on the stock. Piper Sandler reaffirmed an "overweight" rating and set a $20.00 price target on shares of Capricor Therapeutics in a research note on Friday, July 11th. B. Riley began coverage on shares of Capricor Therapeutics in a research report on Thursday, June 26th. They issued a "buy" rating and a $21.00 target price for the company. HC Wainwright reaffirmed a "buy" rating and issued a $24.00 price target on shares of Capricor Therapeutics in a report on Thursday, September 25th. Alliance Global Partners reissued a "buy" rating on shares of Capricor Therapeutics in a research note on Monday, July 14th. Finally, Roth Capital decreased their price objective on shares of Capricor Therapeutics from $31.00 to $12.00 and set a "buy" rating for the company in a report on Monday, July 14th. One analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat.com, Capricor Therapeutics presently has a consensus rating of "Moderate Buy" and an average target price of $22.25.

Capricor Therapeutics Stock Down 0.3%

NASDAQ CAPR traded down $0.02 during trading hours on Wednesday, hitting $7.48. 683,974 shares of the stock were exchanged, compared to its average volume of 1,895,469. The company has a market cap of $341.99 million, a price-to-earnings ratio of -4.56 and a beta of 0.68. Capricor Therapeutics has a 12-month low of $5.68 and a 12-month high of $23.40. The stock has a 50-day moving average of $7.04 and a 200 day moving average of $9.05.

Capricor Therapeutics (NASDAQ:CAPR - Get Free Report) last issued its earnings results on Monday, August 11th. The biotechnology company reported ($0.57) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.48) by ($0.09). On average, equities research analysts expect that Capricor Therapeutics will post -1.21 earnings per share for the current year.

Institutional Investors Weigh In On Capricor Therapeutics

A number of large investors have recently made changes to their positions in the company. Sheets Smith Investment Management acquired a new stake in shares of Capricor Therapeutics during the third quarter valued at approximately $107,000. First Financial Bank Trust Division acquired a new stake in shares of Capricor Therapeutics during the third quarter valued at approximately $203,000. Tower Research Capital LLC TRC raised its holdings in shares of Capricor Therapeutics by 280.8% during the second quarter. Tower Research Capital LLC TRC now owns 6,748 shares of the biotechnology company's stock valued at $67,000 after acquiring an additional 4,976 shares during the period. BNP Paribas Financial Markets increased its stake in Capricor Therapeutics by 2,342.8% in the 2nd quarter. BNP Paribas Financial Markets now owns 36,398 shares of the biotechnology company's stock valued at $361,000 after buying an additional 34,908 shares during the period. Finally, Jump Financial LLC increased its stake in Capricor Therapeutics by 42.6% in the 2nd quarter. Jump Financial LLC now owns 232,536 shares of the biotechnology company's stock valued at $2,309,000 after buying an additional 69,515 shares during the period. Institutional investors and hedge funds own 21.68% of the company's stock.

Capricor Therapeutics Company Profile

Capricor Therapeutics, Inc NASDAQ: CAPR is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor's lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.